News
Inclisiran available in the USA from early January 2022
Hot off the Press: Inclisiran available in the USA from early January 2022 In an ad hoc announcement (pursuant to Art. 53 LR), the US Food and Drugs Administration approved the use of inclisiran, the siRNA therapy for hypercholesterolaemia. Inclisiran is the first and only…
read more »
More insights from ORION
News from AHA Scientific Sessions 2021 Baseline glycaemic status or body mass index (BMI) did not impact the efficacy of inclisiran, according to two post hoc analyses of the ORION trials. The first poster presentation reported findings from a post hoc analysis of the ORION-10…
read more »
Long-term evinacumab in homozygous FH
News from AHA Scientific Sessions 2021 Evinacumab was the focus of two presentations in patients with homozygous familial hypercholesterolaemia (FH, inherited high cholesterol). Homozygous FH is a rare genetic lipid disorder, which is characterized by markedly elevated low-density lipoprotein (LDL) cholesterol levels from birth and…
read more »
Combination alirocumab-evinacumab in homozygous FH
News from AHA Scientific Sessions 2021 Combination treatment with alirocumab plus the angiopoietin-like 3 (ANGPTL3) inhibitor evinacumab, on top of lipid lowering therapy, reduced LDL cholesterol levels by more than 60%, according to a post hoc analysis presented at AHA Scientific Sessions. This report analysed…
read more »
MK-0616: Hope for an oral PCSK9 inhibitor?
News from AHA Scientific Sessions 2021 A novel oral PCSK9 inhibitor, MK-0616, showed substantial reduction in LDL cholesterol levels and was generally well tolerated, according to early trial data. Current PCSK9-directed therapies are undoubtedly effective in lowering LDL cholesterol, against a background of statin-ezetimibe therapy….
read more »
Lipid news from the poster sessions
News from ESC Congress 2021 (Virtual) How common is statin intolerance? The latest findings from a worldwide systematic review and meta-analysis including over 4 million patients indicates a low prevalence of statin intolerance, especially when assessed objectively using recognized international criteria. In this report, the…
read more »
PCSK9-NATURE vindicates targeting LDL cholesterol reduction earlier rather than later
News from ESC Congress 2021 (Virtual) Earlier reduction in LDL cholesterol provides greater lifelong cardiovascular benefit, according to results of PCSK9-NATURE (NATUrally Randomized ‘target’ trial Evaluating a yearly vaccine-like strategy to lower LDL by inhibiting PCSK9 on the lifetime risk of major coronary events), presented…
read more »
Inclisiran effective in patients with polyvascular and cerebrovascular disease
News from ESC Congress 2021 (Virtual). The ESC Congress 2021 featured news from the ORION trials, with subgroup analyses evaluating the efficacy of inclisiran in patients with polyvascular disease (PVD) or cerebrovascular disease. PVD is a particularly malignant atherosclerotic cardiovascular disease (ASCVD) associated with an…
read more »
UK NICE approves use of inclisiran: a gamechanger for patients and the NHS
The siRNA inclisiran is approved by the UK National Institute for Health and Care Excellence (NICE) for use in primary care in England. Inclisiran (Leqvio®), given as a twice-yearly injection, is recommended for people with primary hypercholesterolaemia or mixed dyslipidaemia who have had a previous…
read more »
HUYGENS reinforces the importance of intensive lipid lowering after ACS
News from ESC Congress 2021 (Virtual). Lowering LDL cholesterol indisputably reduces cardiovascular events (1). The landmark PCSK9 inhibitor trials demonstrated that incremental lowering of LDL cholesterol against a background of intense statin therapy further reduced cardiovascular events, with no apparent threshold for clinical benefit from…
read more »
Two Lancet studies make the case for treating high LDL cholesterol in the ‘healthy’ elderly
In the primary prevention setting, individuals aged 75 years or older with elevated LDL cholesterol are at higher absolute cardiovascular risk than those who are younger. These people would gain from lipid lowering treatment, which is as efficacious as in younger age groups. These are…
read more »
News from ODYSSEY OUTCOMES: Lipoprotein(a) lowering is an independent contributor to total cardiovascular event reduction with alirocumab
Lipoprotein(a) lowering contributed to total cardiovascular event reduction in acute coronary syndrome (ACS) patients independent of the effects of alirocumab on LDL cholesterol, according to this analysis of ODYSSEY OUTCOMES. The ODYSSEY OUTCOMES trial previously reported that lowering lipoprotein(a) [Lp(a)] with alirocumab reduced the risk…
read more »
LDL lipidomics: are bioactive lipids biomarkers for cardiometabolic risk?
This report addressed two key questions. Can the bioactive lipid cargo differentiate LDL subclasses, and thus potential atherogenicity? And if so, what is the effect of statin therapy? The human plasma lipidome is composed of many molecular lipid species, showing diverse physicochemical and biological properties….
read more »
Evolocumab with statin/ezetimibe combination may be cost-effective in MI patients: Swedish analysis
An analysis from the Swedish perspective concludes that treatment with the PCSK9 inhibitor evolocumab on top of statin and ezetimibe may be cost-effective in MI patients. While the PCSK9 inhibitors are undoubtedly highly efficacious in lowering LDL cholesterol and reduce cardiovascular events in high and…
read more »
New FOURIER analysis supports aggressive LDL lowering in patients with a recent MI
In this latest FOURIER analysis, add-on evolocumab treatment in patients with a recent myocardial infarction (MI) produced 3-fold greater absolute reduction in cardiovascular risk. These findings confirm 2018 US guideline recommendations for adding a PCSK9 inhibitor in very high-risk patients with elevated LDL cholesterol (≥70…
read more »
VESALIUS-CV: New outcomes study with evolocumab
Amgen has announced a new cardiovascular outcomes study in patients at high risk of cardiovascular events who are already receiving lipid lowering treatment but have not had a previous myocardial infarction (MI) or stroke. VESALIUS-CV is a multinational, double-blind, randomised, placebo-controlled, parallel-group clinical outcomes study…
read more »
Familial hypercholesterolaemia in China – registry urgently needed
The size of the population in China implies a major burden of familial hypercholesterolaemia (FH, inherited high cholesterol). Yet, like the majority of countries world-wide, FH is underdiagnosed and undertreated. China may pose specific issues that contribute to this. Cholesterol levels have been lower in…
read more »
OSLER 5-year data in Japanese: evolocumab continues to impress
Treatment with evolocumab, in addition to standard of care including statin therapy, was well tolerated and led to sustained reduction in LDL cholesterol in Japanese subjects enrolled in the long-term OSLER studies (Open-Label Study of Long-Term Evaluation Against LDL-C). The OSLER studies were designed to…
read more »
Who is receiving PCSK9 inhibitors in the real world?
PCSK9 inhibitors have been endorsed for use in patients at high and very risk of cardiovascular events (1,2). In the real-world, however, which type of patients are more commonly prescribed a PCSK9 inhibitor? Findings based on data from three Danish registries indicate that the majority…
read more »
Cost remains the issue for use of PCSK9 inhibitors
PCSK9 inhibitors are highly efficacious LDL cholesterol lowering treatments that have been endorsed by guidelines and experts for use in very high-risk patients (1-3). The key groups identified by these groups have been patients with clinical atherosclerotic cardiovascular disease (ASCVD), familial hypercholesterolaemia (FH, inherited high…
read more »
